thalidomide has been researched along with Sensation Disorders in 8 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Sensation Disorders: Disorders of the special senses (i.e., VISION; HEARING; TASTE; and SMELL) or somatosensory system (i.e., afferent components of the PERIPHERAL NERVOUS SYSTEM).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide in combination with dexamethasone is an effective and well-established treatment of relapsed or refractory multiple myeloma (rrMM) disease." | 7.80 | Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment. ( Hahn-Ast, C; Kanz, L; Oehrlein, K; Rendl, C; Weisel, K; Zago, M, 2014) |
| " Phase 2 dosing was determined to be bortezomib 1." | 6.75 | Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. ( Anderson, KC; Avigan, DE; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, AJ; Joyce, R; Kaster, S; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Mazumder, A; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, DL; Weller, E; Xie, W, 2010) |
| "There is predominance of paresthesiae in some of them while in others pain or deep sensation failure can dominate." | 5.37 | [Thalidomide-induced sensory neuropaty in patients with multiple myeloma]. ( Bilińska, M; Kuliczkowski, K; Noga, L; Podemski, R; Potoczek, S; Szymczyk, M; Usnarska-Zubkiewicz, L, 2011) |
| " We report the final results of a phase II trial of thalidomide as initial therapy for early-stage multiple myeloma in an attempt to delay progression to symptomatic disease." | 5.10 | Thalidomide as initial therapy for early-stage myeloma. ( Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, SM; Greipp, PR; Iturria, N; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE, 2003) |
| "Lenalidomide in combination with dexamethasone is an effective and well-established treatment of relapsed or refractory multiple myeloma (rrMM) disease." | 3.80 | Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment. ( Hahn-Ast, C; Kanz, L; Oehrlein, K; Rendl, C; Weisel, K; Zago, M, 2014) |
| "Thalidomide was administered as a therapeutic agent for chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in a patient with breast cancer." | 3.69 | Thalidomide-induced perioral neuropathy. ( Elad, S; Galili, D; Garfunkel, AA; Or, R, 1997) |
| " Phase 2 dosing was determined to be bortezomib 1." | 2.75 | Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. ( Anderson, KC; Avigan, DE; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, AJ; Joyce, R; Kaster, S; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Mazumder, A; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, DL; Weller, E; Xie, W, 2010) |
| "Thalidomide was used for graft-vs-host disease, pyoderma gangrenosum, and discoid lupus with dosages ranging from 100 to 1,200 mg/day for 5 to 16 months (cumulative dosages of 24 to 384 g)." | 2.70 | Thalidomide-induced neuropathy. ( Chaudhry, V; Cornblath, DR; Corse, A; Freimer, M; Simmons-O'Brien, E; Vogelsang, G, 2002) |
| "Four patients died due to disease progression and 17 were found to have progressed after ASCT (the median progression-free survival after ASCT was 19." | 1.40 | Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation. ( Chang, WJ; Kang, ES; Kim, DW; Kim, K; Kim, SH; Kim, SJ; Lee, ST, 2014) |
| "There is predominance of paresthesiae in some of them while in others pain or deep sensation failure can dominate." | 1.37 | [Thalidomide-induced sensory neuropaty in patients with multiple myeloma]. ( Bilińska, M; Kuliczkowski, K; Noga, L; Podemski, R; Potoczek, S; Szymczyk, M; Usnarska-Zubkiewicz, L, 2011) |
| " The threshold neurotoxic dosage is lower than previously reported." | 1.35 | Thalidomide and sensory neurotoxicity: a neurophysiological study. ( Arienti, S; Doria, A; Ermani, M; Rondinone, R; Zara, G, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, WJ | 1 |
| Kang, ES | 1 |
| Lee, ST | 1 |
| Kim, SH | 1 |
| Kim, DW | 1 |
| Kim, SJ | 1 |
| Kim, K | 1 |
| Zago, M | 1 |
| Oehrlein, K | 1 |
| Rendl, C | 1 |
| Hahn-Ast, C | 1 |
| Kanz, L | 1 |
| Weisel, K | 1 |
| Richardson, PG | 1 |
| Weller, E | 1 |
| Lonial, S | 1 |
| Jakubowiak, AJ | 1 |
| Jagannath, S | 1 |
| Raje, NS | 1 |
| Avigan, DE | 1 |
| Xie, W | 1 |
| Ghobrial, IM | 1 |
| Schlossman, RL | 1 |
| Mazumder, A | 1 |
| Munshi, NC | 1 |
| Vesole, DH | 1 |
| Joyce, R | 1 |
| Kaufman, JL | 1 |
| Doss, D | 1 |
| Warren, DL | 1 |
| Lunde, LE | 1 |
| Kaster, S | 1 |
| Delaney, C | 1 |
| Hideshima, T | 1 |
| Mitsiades, CS | 1 |
| Knight, R | 1 |
| Esseltine, DL | 1 |
| Anderson, KC | 1 |
| Bilińska, M | 1 |
| Usnarska-Zubkiewicz, L | 1 |
| Szymczyk, M | 1 |
| Noga, L | 1 |
| Potoczek, S | 1 |
| Kuliczkowski, K | 1 |
| Podemski, R | 1 |
| Chaudhry, V | 1 |
| Cornblath, DR | 1 |
| Corse, A | 1 |
| Freimer, M | 1 |
| Simmons-O'Brien, E | 1 |
| Vogelsang, G | 1 |
| Rajkumar, SV | 1 |
| Gertz, MA | 1 |
| Lacy, MQ | 1 |
| Dispenzieri, A | 1 |
| Fonseca, R | 1 |
| Geyer, SM | 1 |
| Iturria, N | 1 |
| Kumar, S | 1 |
| Lust, JA | 1 |
| Kyle, RA | 1 |
| Greipp, PR | 1 |
| Witzig, TE | 1 |
| Zara, G | 1 |
| Ermani, M | 1 |
| Rondinone, R | 1 |
| Arienti, S | 1 |
| Doria, A | 1 |
| Elad, S | 1 |
| Galili, D | 1 |
| Garfunkel, AA | 1 |
| Or, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma[NCT02103335] | Phase 1 | 38 participants (Actual) | Interventional | 2014-06-05 | Completed | ||
| Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance[NCT01647165] | Phase 2 | 0 participants (Actual) | Interventional | 2012-07-11 | Withdrawn | ||
| A Pilot Study on the Efficacy of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive by Next Generation Flow[NCT03992170] | Phase 2 | 50 participants (Anticipated) | Interventional | 2018-12-31 | Recruiting | ||
| An Open-Label Phase I/II Study of the Safety and Efficacy of Bortezomib, Lenalidomide and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma[NCT00378105] | Phase 1/Phase 2 | 68 participants (Actual) | Interventional | 2006-09-30 | Active, not recruiting | ||
| A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma[NCT04009109] | Phase 2 | 188 participants (Anticipated) | Interventional | 2020-10-21 | Recruiting | ||
| QUIREDEX: A National, Open-Label, Multicenter, Randomized, Phase III Study of Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression[NCT00480363] | Phase 3 | 120 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall survival was measured from treatment initiation to death, censored at the date patients were last known to be alive for those who had not died. (NCT00378105)
Timeframe: Survival rate at 18 months
| Intervention | Percentage of participants (Number) |
|---|---|
| All Patients | 97 |
"PD from European Bone Marrow Transplant (EBMT) Response Criteria Required one or more:~>25% increased in the level of serum monoclonal paraprotein, which must also be an absolute increase of at least 5 g/L and confirmed on a repeat investigation, or >25% increased in 24-hour urinary light chain excretion (must also be an absolute increase of at least 200 mg/24 h and confirmed on a repeat investigation), or >25% increased in plasma cells in a bone marrow aspirate or biopsy (must also be an absolute increase of at least 10%) Definite increase in the size of existing lytic bone lesions or soft tissue plasmacytomas.~Development of new bone lesions or soft tissue plasmacytomas (not including compression fracture).~Development of hypercalcemia (corrected serum calcium >11.5 mg/dL or 2.8 mmol/L not attributable to any other cause).~PFS was measured from treatment initiation to progression or death, censored at the date patients were last known to be alive and disease free" (NCT00378105)
Timeframe: PFS rate at 18 months
| Intervention | Percentage of participants (Number) |
|---|---|
| All Patients | 75 |
Overall Response (OR) was defined as partial response (PR) or better. Response was assessed according to European Group for Blood and Marrow Transplant criteria, modified to include nCR and VGPR, from the International Uniform Response Criteria. (NCT00378105)
Timeframe: Full response assessment was conducted at the end of cycle 8 (average of168 days) and after cycle 4 (84 days) for patients proceeding to transplant.
| Intervention | percentage of participants (Number) |
|---|---|
| Phase 1 Population | 100 |
| Phase II Population | 100 |
| Total | 100 |
Duration of response was measured from first response to progression or death, censored at the date patients were last known to be alive and disease free for patients who had not progressed or died. (NCT00378105)
Timeframe: Response rate at 18 months
| Intervention | Percentage of participants (Number) |
|---|---|
| All Patients | 68 |
3 trials available for thalidomide and Sensation Disorders
| Article | Year |
|---|---|
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Thalidomide-induced neuropathy.
Topics: Adult; Bone Marrow Transplantation; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; | 2002 |
Thalidomide as initial therapy for early-stage myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bradycardia; Constipation; Disease Progression; Disease-Free Sur | 2003 |
Thalidomide as initial therapy for early-stage myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bradycardia; Constipation; Disease Progression; Disease-Free Sur | 2003 |
Thalidomide as initial therapy for early-stage myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bradycardia; Constipation; Disease Progression; Disease-Free Sur | 2003 |
Thalidomide as initial therapy for early-stage myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bradycardia; Constipation; Disease Progression; Disease-Free Sur | 2003 |
5 other studies available for thalidomide and Sensation Disorders
| Article | Year |
|---|---|
Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Constipation; Cycl | 2014 |
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Boronic | 2014 |
[Thalidomide-induced sensory neuropaty in patients with multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Electrodiagnosis; Female; Humans; Male; Middle Aged; Multiple Myelom | 2011 |
Thalidomide and sensory neurotoxicity: a neurophysiological study.
Topics: Adult; Angiogenesis Inhibitors; Disability Evaluation; Female; Humans; Lupus Erythematosus, Cutaneou | 2008 |
Thalidomide-induced perioral neuropathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adju | 1997 |